These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 9631026)

  • 1. Cassava R&D: a public investment.
    Thro AM
    Nat Biotechnol; 1996 Aug; 14(8):929. PubMed ID: 9631026
    [No Abstract]   [Full Text] [Related]  

  • 2. The benefits of biomedical research. FASEB Office of Public Affairs.
    Physiologist; 1999 Dec; 42(6):389, 392-5. PubMed ID: 10645140
    [No Abstract]   [Full Text] [Related]  

  • 3. Private investment in AIDS vaccine development: obstacles and solutions.
    Batson A; Ainsworth M
    Bull World Health Organ; 2001; 79(8):721-7. PubMed ID: 11545328
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Life support for life science innovation?
    Nat Biotechnol; 2007 Feb; 25(2):144. PubMed ID: 17287731
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Agencies must show that basic research is worth the investment.
    Nature; 2016 Jul; 535(7613):465. PubMed ID: 27466088
    [No Abstract]   [Full Text] [Related]  

  • 6. The global cassava partnership for genetic improvement.
    Fauquet CM; Tohme J
    Plant Mol Biol; 2004 Nov; 56(4):v-x. PubMed ID: 15630614
    [No Abstract]   [Full Text] [Related]  

  • 7. Japanese firms broaden investment focus to early biotech.
    Louët S; Sipp D
    Nat Biotechnol; 2004 Aug; 22(8):931-2. PubMed ID: 15286631
    [No Abstract]   [Full Text] [Related]  

  • 8. Biotech R&D goes further afield.
    Lawrence S
    Nat Biotechnol; 2006 Sep; 24(9):1052. PubMed ID: 16964201
    [No Abstract]   [Full Text] [Related]  

  • 9. Cassava, Manihot esculenta Crantz, genetic resources: origin of the crop, its evolution and relationships with wild relatives.
    Nassar NM
    Genet Mol Res; 2002 Dec; 1(4):298-305. PubMed ID: 14963820
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The emerging role of academia in commercializing innovation.
    Mehta S
    Nat Biotechnol; 2004 Jan; 22(1):21-4. PubMed ID: 14704695
    [No Abstract]   [Full Text] [Related]  

  • 11. Capturing discovery.
    Dagnone T; Gleeson F
    Leadersh Health Serv; 1996; 5(3):34-8. PubMed ID: 10158409
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Taiwan: Biotech vision.
    Cyranoski D
    Nat Biotechnol; 2003 Apr; 21(4):463-4. PubMed ID: 12665831
    [No Abstract]   [Full Text] [Related]  

  • 13. Enabling Europe to innovate.
    Dearing A
    Science; 2007 Jan; 315(5810):344-7. PubMed ID: 17234939
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gene flow between cassava, Manihot esculenta Crantz, and wild relatives.
    Nassar NM
    Genet Mol Res; 2003 Dec; 2(4):334-47. PubMed ID: 15011137
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Breeding cassava for apomixis.
    Nassar NM; Collevatti RG
    Genet Mol Res; 2005 Dec; 4(4):710-5. PubMed ID: 16475116
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Microsatellite markers confirm high apomixis level in cassava bred clones.
    Nassar NM; Collevatti RG
    Hereditas; 2005 Feb; 142(2005):33-7. PubMed ID: 16970609
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Counting the cost.
    Powell K
    Nature; 2005 Apr; 434(7036):1048-9. PubMed ID: 15846352
    [No Abstract]   [Full Text] [Related]  

  • 18. Cassava, Manihot esculenta Crantz genetic resources: VI. Anatomy of a diversity center.
    Nassar NM
    Genet Mol Res; 2003 Jun; 2(2):214-22. PubMed ID: 14966687
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The 802 million dollars fallacy.
    Hodgson J
    Nat Biotechnol; 2004 Sep; 22(9):1076. PubMed ID: 15340464
    [No Abstract]   [Full Text] [Related]  

  • 20. Industry concerns mount over CIRM grants.
    Baker M
    Nat Biotechnol; 2007 Oct; 25(10):1063-4. PubMed ID: 17921974
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.